Grépin, Renaud <br/><br/>
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.  [electronic resource] 

 -  PloS one  2014 
 - e89449 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0089449  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--pharmacology<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Basic Helix-Loop-Helix Leucine Zipper Transcription Factors--genetics<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease Models, Animal<br/>Drug Resistance, Neoplasm<br/>Female<br/>Gene Expression<br/>Humans<br/>Indoles--pharmacology<br/>Kidney Neoplasms--drug therapy<br/>Mice<br/>Molecular Targeted Therapy<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Neovascularization, Pathologic--drug therapy<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds--pharmacology<br/>Precision Medicine<br/>Pyrroles--pharmacology<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Sorafenib<br/>Sunitinib<br/>Tumor Cells, Cultured<br/>Xenograft Model Antitumor Assays